Blue Lake Biotechnology
Blue Lake Biotech, a Georgia-based startup, develops novel viral vector vaccines, initially targeting respiratory diseases.
Founded
2019Blue Lake Biotech, a Georgia-based startup, develops novel viral vector vaccines, initially targeting respiratory diseases.
Blue Lake Biotechnology, founded in 2019 by Biao He in Athens, Georgia, is dedicated to developing innovative intranasal vaccines using a proprietary viral vector platform. The company's core mission is to harness the full breadth of the immune system to prevent serious infectious diseases and protect vulnerable populations. Initially focusing on respiratory syncytial virus (RSV), Blue Lake aims to advance its PIV5-based vaccines through clinical trials and achieve FDA approval.
Notable figures associated with Blue Lake Biotechnology include its founder, Biao He, who brings significant expertise in virology and vaccine development. The company has made significant strides in its field, with key achievements including the progression towards FDA approval for phase I trials of its RSV vaccine. Blue Lake's impact lies in its potential to revolutionize vaccine delivery and efficacy, particularly for respiratory diseases, thereby contributing to global health advancements.
Companies similar to Blue Lake Biotechnology include BlueWillow Biologics, Vivaldi Biosciences, Great Lakes Biologics and Uvax Bio.
Blue Lake Biotechnology was founded in 2019.
Blue Lake Biotechnology's headquarters is located in Athens, GA, US.
Blue Lake Biotechnology's most recent funding round was for $8.8M (USD) in December 2019.
As of Dec 27, 2019, Blue Lake Biotechnology has disclosed funding of $8.8M (USD). Undisclosed round amounts are excluded.
Blue Lake Biotechnology has 10 employees as of Feb 5, 2024.
Uvax Bio
uvaxbio.com
